CORAL GABLES, FL / ACCESSWIRE / March 19, 2015 / Globally, the market for biotechnology has been growing at a rate of over 10% annually according to a report from IBISWorld. Annual revenue is on the cusp of breaking $290 Billion and has many sub sectors contributing to its further expansion. Industry firms have thrived as technological advances have facilitated new discoveries and ignited higher demand from firms in the pharmaceuticals and agricultural sectors. According to the report, industry growth is forecast to continue "skyrocketing in the next five-year period" where investment in biotechnology from around the world increases, particularly from emerging economies.

From new drug discovery from companies like Oxis International (OXIS) and Rich Pharmaceuticals (RCHA) to advanced technology like that of PositiveID Corp (PSID), the marketplace for biotech and biotech stocks continues to grow.

In a recent press release, PositiveID announced that it had filed an additional patent for its Firefly DX Real Time PCR System. If you're unfamiliar with what this is, Firefly Dx is designed to provide "real-time, accurate diagnostic results using polymerase chain reaction (PCR) chemistry in a handheld device." According to the company, this leads to treatment scenarios at the point of need that are not possible with existing systems and it also provides results in less than 20 minutes. Many uses include monitoring for pathogenic outbreaks like the recent Ebola epidemic, agriculture screening, and biological agents associated with weapons of mass destruction. According to Research and Markets, the Global PCR market is projected to reach approximately $27.4 Billion in 2015. Recent trading in the market for PSID has begun to pick up steam as above average trading volume has seen this stock as high as $0.029 just a few days ago.

From a medical perspective, a company like Oxis International is taking a different angle on biotech and focusing on medical applications for certain cancers using cannabinoids. In fact, just last week the company announced the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates thought to be useful for the treatment of triple-negative breast cancer, and multiple myeloma. Since kicking off the year, Oxis International has also begun to see an increase in trading volume. Since the beginning of January, the stock has seen prices as high as $0.06 and trading topping out at nearly 18 million shares on certain instances.

In similar fashion Rich Pharmaceuticals is in the clinical stages of developing therapies concentrating initially on the treatment of Acute Myelocytic Leukemia. Since seeing explosive price movement earlier in February, it has seen considerable amounts of consolidation back to a level it was trading at prior to that price jump. In recent news, management announced that Dr. Chittima Sirijerachai has committed to becoming a principal investigator for the upcoming AML clinical trial utilizing Rich's flagship compound RP-323.

ABOUT US:

www.DailyStockReporter.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals www.DailyStockReporter.com is often in the know of several large investor awareness campaigns being deployed. Timing is everything when trading Penny Stocks. Subscribe to the www.DailyStockReporter.com newsletter and start receiving daily alerts. Subscribe Here: http://www.DailyStockReporter.com/.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. EGM FIRM INC which owns www.DailyStockReporter.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. EGM FIRM INC which owns www.DailyStockReporter.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. EGM FIRM INC which owns www.DailyStockReporter.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

CONTACT:

Company: DailyStockReporter.com
Contact Name: Adam Heimann
Contact Email: adam@egmfirm.com

SOURCE: DailyStockReporter.com